Related Experiment Videos
Alendronate disturbs vesicular trafficking in osteoclasts
A Alakangas1, K Selander, M Mulari
1Institute of Biomedicine, Department of Anatomy, University of Turku, Kiinamyllynkatu 10, 20520 Turku, Finland.
Abstract:
The nitrogen-containing bisphosphonate alendronate inhibits osteoclast-mediated bone resorption through inhibition of the mevalonate pathway. This results in impaired protein prenylation and may affect the function of small GTPases in osteoclasts. Since these proteins are important regulators of vesicle transport in cells, we investigated the possible interference of alendronate with these processes in isolated rat osteoclasts. We show here that alendronate-induced inhibition of bone resorption coincides with accumulation of tartrate-resistant acid phosphatase- and electron dense material-containing tubular vesicles in osteoclasts. Alendronate-induced changes in osteoclasts also included widening of the sealing zone areas and incomplete organization of tight attachments and ruffled borders. Osteoclasts also appeared partially detached from the bone surface, and organic matrix was typically dissolved only at the edges of the resorption pits on alendronate-coated bone slices. In contrast, resorption pits on the control and clodronate-coated bone slices were thoroughly resorbed. Inhibition of bone resorption by alendronate was not, however, related to a decrease in osteoclast number. In conclusion, our findings suggest that alendronate inactivates osteoclasts by mechanisms that impair their intracellular vesicle transport, apoptosis being only a secondary phenomenon to this.
Insights
Alendronate, a bisphosphonate drug, stops bone breakdown by disrupting osteoclast vesicle transport. This impairs osteoclast function, leading to reduced bone resorption without decreasing osteoclast numbers.
Area of Science:
- Biochemistry
- Cell Biology
- Pharmacology
Background:
- Nitrogen-containing bisphosphonates like alendronate inhibit bone resorption.
- Alendronate targets the mevalonate pathway, affecting protein prenylation and small GTPase function in osteoclasts.
Purpose of the Study:
- To investigate alendronate's interference with vesicle transport in isolated rat osteoclasts.
- To elucidate the cellular mechanisms underlying alendronate's inhibition of bone resorption.
Main Methods:
- Isolated rat osteoclasts were treated with alendronate.
- Bone resorption was assessed on alendronate-coated bone slices.
- Ultrastructural changes in osteoclasts were examined using electron microscopy.
Main Results:
- Alendronate treatment led to the accumulation of tartrate-resistant acid phosphatase- and electron-dense material-containing tubular vesicles.
- Osteoclast changes included widened sealing zones, disorganized attachments, and incomplete ruffled borders.
- Bone resorption was inhibited, with dissolution limited to pit edges, and osteoclast numbers remained unchanged.
Conclusions:
- Alendronate inactivates osteoclasts by impairing intracellular vesicle transport.
- Apoptosis is a secondary effect, not the primary mechanism of alendronate-induced osteoclast inactivation.